Cargando…
The clinical efficacy and safety of certolizumab pegol (CZP) in the treatment of rheumatoid arthritis: focus on long-term use, patient considerations and the impact on quality of life
Rheumatoid arthritis can cause chronic pain, disability, fatigue and loss of productivity both in the workplace and at home. Fatigue, not joint pain, swelling or that there may be radiographic damage, is frequently mentioned by patients as their most debilitating problem. In the era prior to biologi...
Autor principal: | Fleischmann, Roy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074715/ https://www.ncbi.nlm.nih.gov/pubmed/27789984 |
Ejemplares similares
-
Long-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis Patients
por: Fleischmann, Roy, et al.
Publicado: (2017) -
Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol
por: Barnes, Theresa, et al.
Publicado: (2007) -
Clinical, Ultrasound, and Predictability Outcomes Following Certolizumab Pegol Treatment (with Methotrexate) in Patients with Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results from the CZP-SPEED Study
por: Sarzi-Puttini, Piercarlo, et al.
Publicado: (2018) -
Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial
por: Atsumi, Tatsuya, et al.
Publicado: (2017) -
Certolizumab pegol in the treatment of rheumatoid arthritis: a comprehensive review of its clinical efficacy and safety
por: Mease, Philip J.
Publicado: (2011)